 The aim of the study is to investigate the trial models, Vienna Challenge Chamber VCC, in and out of season, and Park Study in season and the clinical efficacy of repeat doses of fluticasone propionate in subjects with seasonal allergic rhinitis. This will be a single-centre, randomised, double-blind, placebo-controlled, 3 phase study in 40 male or female subjects with seasonal allergic rhinitis. The subjects will be randomised to receive either fluticasone propionate aqueous nasal spray or matched placebo. The study consists of three phases with each phase consists of 2 treatment periods. A screening visit will be followed by Phase 1 Vienna Chamber Challenge out of season, Phase 2 Park Study, in season and Phase 3 Vienna Chamber Challenge in season. There will be a follow-up visit after Phase 1 and Phase 2 3 will be separated by a 10 day wash-out period. A follow-up visit will be completed 7-14 days after the last received dose. Intranasal fluticasone propionate will be administered daily for 8 days in the VCC and up to 14 days in the Park Study. Primary assessment will consist of major symptoms complex MSC during a 5-hour pollen allergen challenge in the Vienna Challenge Chamber VCC following final dosing on Day 8 and following final dosing between Day 8 and Day 14 in the Park Study. In addition, nasal flow measured by anterior rhinomanometry, wet tissue weight as a surrogate of nasal secretion and categorical scores for ocular symptoms, cough, itchy throat and itchy ears will be measured on day 8 VCC or on a day between 8-14 Park. 